July, 2025 - Kan and Krishme

July 25, 2025
Blog
No Comments

Understanding the Difference between Section 3(d) and 3(e) through Oramed

Introduction In a recent judgment dated July 4, 2025, the Calcutta High Court in Oramed Ltd. vs The Controller General of Patents 1overturned a patent refusal order for Application No. 3996/KOLNP/2010, which the Indian Patent Office had rejected on the grounds of lack of inventiveness under Section 2(1)(ja) and non-patentability under Section 3(e) of the […]

July 25, 2025
Blog
No Comments

Delhi High Court Reaffirms Inventive Step Must Be Evidence-Based, Not Assumption-Driven

Introduction In the fast-evolving world of intellectual property, patent applicants often face procedural and substantive hurdles—especially when navigating oppositions and prior art disclosures. In DONG YANG PC, INC. v. Controller of Patents and Designs, the Korean innovator in automated parking systems challenged the rejection of its Indian patent application on two key grounds: (1) that […]

July 25, 2025
Blog
No Comments

Draft Version 2.0 CRI Guidelines 2025: Understanding the Changes and their Impact

Introduction The Indian Patent Office’s Computer Related Inventions (CRI) Guidelines 2025 have undergone some revisions in its second draft, shaping the way patentability is assessed for innovations in fields like Artificial Intelligence (AI), Blockchain, Quantum Computing, and more. These changes aim to enhance clarity, fairness, and consistency in patent examination while fostering innovation in emerging […]

July 25, 2025
Blog
No Comments

Protecting IP in a Global Market: Delhi HC’s Strategic Use of Section 151 CPC

Introduction The Delhi High Court recently addressed a pressing issue in Communication Components Antenna Inc. v. Ace Technologies Corp. and Ors1: how can Indian patent holders enforce their rights when foreign infringers have no assets in India? The case involved a cross-border patent dispute where the defendants, based in South Korea and Hong Kong, were […]

July 18, 2025
Blog
No Comments

Delhi High Court Reiterates Limits on Patentability of Software-Based Inventions

On July 1, 2025, in Kroll Information Assurance, LLC v. The Controller General of Patents, Designs and Trademarks & Ors.1, the Delhi High Court upheld the refusal of a patent application under Section 3(k) of the Indian Patents Act, 1970, reaffirming that a mere sequence of instructions or abstract profiling logic is insufficient for patent […]

July 18, 2025
Blog
No Comments

MS Dhoni’s Quest to Trademark “Captain Cool”

In June 2023, legendary former Indian cricket captain Mahendra Singh Dhoni took a significant step by filing a trademark application for his well-known nickname, “Captain Cool.” The application was submitted by Rithi Sports Management Pvt Ltd, a company associated with Dhoni, to the Trade Marks Registry. The mark was filed under Class 41, which covers […]

July 18, 2025
Blog
No Comments

Delhi High Court Stays Multimillion Dollar Decree against Amazon

Introduction On July 1, 2025, the Delhi High Court passed a significant order 1staying the execution of a ₹336 crore (approx. USD 38.8 million) decree awarded against Amazon Technologies Inc. in a trademark infringement suit initiated by Lifestyle Equities CV and Lifestyle Licensing BV—entities associated with the Beverly Hills Polo Club (BHPC) brand. This stay […]

July 11, 2025
Blog
No Comments

How Delay and Non-Use Undid Conqueror’s Claims Against Xiaomi

Introduction How Delay and Non-Use Undid Conqueror’s Claims Against Xiaomi The Delhi High Court’s decision in Conqueror Innovations Private Limited & Anr. v. Xiaomi Technology India Private Limited1 [1] offers a meticulous exploration of patent infringement claims and the high threshold required for interim relief in Indian patent litigation. Justice Amit Bansal’s judgment, pronounced on […]

July 11, 2025
Blog
No Comments

A Weighty Dispute: Novo Nordisk’s Semaglutide Patent Clash in Delhi High Court

Introduction A major patent battle [1] has erupted in India between pharmaceutical giants Novo Nordisk and Dr. Reddy’s Laboratories over the popular weight loss and diabetes drug semaglutide. Novo Nordisk sued Dr. Reddy’s for manufacturing and exporting its patented drug without consent. This case is significant for the Indian pharmaceutical industry, as its outcome will […]